The identification of ITGB3 as a potential SSRI response biomarker was further supported by our recent study in which lower ITGB3 expression levels (~50% vs. healthy controls) were observed in peripheral blood mononuclear cells (PBMCs) obtained from MDD patients (Rzezniczek et al., 2016). This evidence concerns the gene ITGB3 and major depressive disorder.